1h Free Analyst Time
According to the recently published report 'Hepatocyte Growth Factor - Drugs In Development, 2022'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 19 molecules. Out of which approximately 19 molecules are developed by Companies. Speak directly to the analyst to clarify any post sales queries you may have.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
The report 'Hepatocyte Growth Factor - Drugs In Development, 2022' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 1, 6 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Dermatology, Genetic Disorders, Hematological Disorders and Respiratory which include indications Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Melanoma, Ovarian Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Alzheimer's Disease, Anxiety Disorders, Arteriosclerosis, Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Colorectal Cancer, Dementia, Depression, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Gastric Cancer, Hepatocellular Carcinoma, Intermittent Claudication, Leiomyosarcoma, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Occlusive Arterial Disease (OAD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Schizophrenia, Solid Tumor, Thromboangiitis obliterans (Buerger disease) and Ulcers.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
- AnGes Inc
- Athira Pharma Inc
- AVEO Pharmaceuticals Inc
- Beijing SH biotechnology Co Ltd
- G&P Bioscience Co Ltd
- Helixmith Co Ltd
- i2 Pharmaceuticals Inc
- Kringle Pharma Inc
- Minerva Biotechnologies Corp
- Molecular Partners AG
- PlateletBio
- Yichang Humanwell Pharmaceutical Co Ltd
- Yooyoung Pharm Co Ltd
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
- Ad-HGF - Drug Profile
- Product Description
- Mechanism Of Action
- ATH-1020 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- beperminogene perplasmid - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- donaperminogene seltoplasmid - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ficlatuzumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fosgonimeton - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to activate HGF for Lung Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- MP-0250 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NK-4 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- oremepermin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SL-186 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SL-188 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- YYB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
- Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
- Featured News & Press Releases
- Jul 25, 2022: Athira Pharma to present clinical and preclinical data at Alzheimer’s Association International Conference 2022
- Jun 22, 2022: Athira Pharma announces topline results from ACT-AD Phase 2 proof of concept study of Fosgonimeton in mild-to-moderate Alzheimer’s disease
- May 09, 2022: Athira Pharma extends ongoing open label extension study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for mild to moderate Alzheimer’s Disease
- May 02, 2022: Helixmith announces VM202 (Engensis) presentation at New York Academy of Sciences "Advances in Pain" Meeting on May 3, 2022
- Apr 05, 2022: Athira doses first subject in Phase I neuropsychiatric treatment trial
- Mar 30, 2022: Athira Pharma highlights strong execution of strategy and positioning for the future
- Mar 20, 2022: Athira Pharma presents study overview and baseline data from ACT-AD phase 2 trial of Fosgonimeton in mild-to-moderate Alzheimer’s Disease at the 2022 AD/PD Congress
- Mar 14, 2022: Athira Pharma to present overview and update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s disease at AD/PD 2022 Congress
- Mar 14, 2022: Paper reporting results from Helixmith's phase 3 gene therapy trial for painful diabetic neuropathy was one of the top-10 most-downloaded articles in Clinical and Translational Science
- Feb 22, 2022: Athira Pharma to present preclinical data at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
- Feb 22, 2022: Athira Pharma to present preclinical data of fosgonimeton at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
- Feb 22, 2022: Athira Pharma announces publication of phase 1 results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
- Jan 25, 2022: Athira Pharma announces initiation of patient dosing in SHAPE, a phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's Disease dementia and dementia with lewy bodies
- Dec 09, 2021: Kringle Pharma announces last patient out in phase 2 study of KP-100IT for the treatment of ALS
- Nov 10, 2021: Athira Pharma presents overview and update from ACT-AD and LIFT-AD trials of ATH-1017 in mild-to-moderate Alzheimer’s disease at CTAD Conference
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AnGes Inc, 2022
- Pipeline by Athira Pharma Inc, 2022
- Pipeline by AVEO Pharmaceuticals Inc, 2022
- Pipeline by Beijing SH biotechnology Co Ltd, 2022
- Pipeline by G&P Bioscience Co Ltd, 2022
- Pipeline by Helixmith Co Ltd, 2022
- Pipeline by i2 Pharmaceuticals Inc, 2022
- Pipeline by Kringle Pharma Inc, 2022
- Pipeline by Minerva Biotechnologies Corp, 2022
- Pipeline by Molecular Partners AG, 2022
- Pipeline by PlateletBio, 2022
- Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
- Pipeline by Yooyoung Pharm Co Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AnGes Inc
- Athira Pharma Inc
- AVEO Pharmaceuticals Inc
- Beijing SH biotechnology Co Ltd
- G&P Bioscience Co Ltd
- Helixmith Co Ltd
- i2 Pharmaceuticals Inc
- Kringle Pharma Inc
- Minerva Biotechnologies Corp
- Molecular Partners AG
- PlateletBio
- Yichang Humanwell Pharmaceutical Co Ltd
- Yooyoung Pharm Co Ltd
